Biologic ‘should be first line for pemphigus’
A treatment regime including intravenous rituximab is superior to conventional management, dermatologists say
Australian guidelines for managing pemphigus diseases should be updated to include the anti-CD20 monoclonal antibody rituximab as a first-line therapy option, clinicians urge.
They say current advice for oral prednisolone 1-1.5mg/kg/day alone or with immunosuppressants to be used first line in moderate or severe pemphigus has been overtaken by “overwhelming evidence” for the biologic.
